Literature DB >> 10514396

Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival.

J J Del Pizzo1, A Borkowski, S C Jacobs, N Kyprianou.   

Abstract

The cyclin-dependent kinase inhibitor p27(Kip1) is a powerful molecular determinant of cell cycle progression. Loss of expression of p27(Kip1) has been shown to be predictive of disease progression in several human malignancies. In this study we investigated the expression of two key cell cycle regulators, p27(Kip1) and cyclin E, in the progression of transitional cell carcinoma of the bladder. An immunohistochemical analysis was conducted in a series of 50 bladder tumor specimens, including 3 metastatic lymph nodes, and 7 normal bladder specimens, using specific antibodies against the two regulators of the cell cycle, p27(Kip1) and cyclin E. The degree of immunoreactivity was correlated with the pathological tumor grade, stage, and patient survival. A uniformly intense immunoreactivity for p27(Kip1) and cyclin E was observed in epithelial cells of normal bladder tissue. Malignant bladder tissue demonstrated a heterogeneous pattern of significantly reduced p27(Kip1) and cyclin E immunoreactivity, compared with normal urothelium (P < 0.01). In addition, there was progressive loss of expression of both cell cycle proteins with increasing tumor grade and pathological stage. Expression of p27(Kip1) was significantly lower in the poorly differentiated tumors (grades III) compared to well and moderately differentiated (grades I and II) tumors (P = 0.004). Moreover, the expression of cyclin E was lower in grade III tumors compared to grade I and II lesions, although this difference failed to reach statistical significance. Most significantly, Kaplan-Meier plots of patient survival show increased mortality risk associated with low levels of p27(Kip1) (P = 0.001) and cyclin E (P = 0.002) expression. This is the first evidence that loss of expression of p27(Kip1) and cyclin E in human bladder transitional cell carcinoma cells correlates with advancing histological aggressiveness and poor patient survival. These results have clinical importance, because they support a role for p27(Kip1) and cyclin E as novel predictive markers of the biological potential of bladder tumors that will enable identification of those tumors most likely to progress to muscle invasive disease and of patient survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514396      PMCID: PMC1867023          DOI: 10.1016/S0002-9440(10)65216-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

Review 1.  G1 events and regulation of cell proliferation.

Authors:  A B Pardee
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

2.  Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.

Authors:  C Cordon-Cardo; D Wartinger; D Petrylak; G Dalbagni; W R Fair; Z Fuks; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1992-08-19       Impact factor: 13.506

3.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

4.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.

Authors:  C Cordon-Cardo; A Koff; M Drobnjak; P Capodieci; I Osman; S S Millard; P B Gaudin; M Fazzari; Z F Zhang; J Massague; H I Scher
Journal:  J Natl Cancer Inst       Date:  1998-09-02       Impact factor: 13.506

Review 5.  Prognostic markers in bladder cancer: a contemporary review of the literature.

Authors:  J P Stein; G D Grossfeld; D A Ginsberg; D Esrig; J A Freeman; A J Figueroa; D G Skinner; R J Cote
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

6.  Overexpression of p27Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells.

Authors:  A Sgambato; Y J Zhang; M Ciaparrone; J W Soh; A Cittadini; R M Santella; I B Weinstein
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

7.  Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer.

Authors:  W Jiang; Y J Zhang; S M Kahn; M C Hollstein; R M Santella; S H Lu; C C Harris; R Montesano; I B Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.

Authors:  Y Guo; G N Sklar; A Borkowski; N Kyprianou
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

9.  Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes.

Authors:  S P Hussain; C C Harris
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

10.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

View more
  19 in total

1.  Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer.

Authors:  Liuxia Li; Kaijuan Wang; Liping Dai; Peng Wang; Xuan-Xian Peng; Jian-Ying Zhang
Journal:  Mol Med Rep       Date:  2008 Jul-Aug       Impact factor: 2.952

Review 2.  Cell cycle control as a basis for cancer chemoprevention through dietary agents.

Authors:  Syed Musthapa Meeran; Santosh Kumar Katiyar
Journal:  Front Biosci       Date:  2008-01-01

3.  Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Authors:  Said Akli; Xin-Qiao Zhang; Jolanta Bondaruk; Susan L Tucker; P Bogdan Czerniak; William F Benedict; Khandan Keyomarsi
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

4.  Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.

Authors:  N Kato; J Watanabe; T Jobo; Y Nishimura; T Fujisawa; Y Kamata; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-08       Impact factor: 4.553

5.  High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer.

Authors:  J Richter; U Wagner; J Kononen; A Fijan; J Bruderer; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; K Wilber; M Anabitarte; F Hering; T Hardmeier; A Schönenberger; R Flury; P Jäger; J L Fehr; P Schraml; H Moch; M J Mihatsch; T Gasser; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

6.  P27(Kip1) and Ki-67 expression analysis in transitional cell carcinoma of the bladder.

Authors:  Bartosz Dybowski; Jolanta Kupryjańczyk; Alina Rembiszewska; Roman Pykało; Andrzej Borkowski
Journal:  Urol Res       Date:  2003-09-27

7.  Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?

Authors:  Latife Doganay; Semsi Altaner; Selcuk Bilgi; Esat Kaya; Galip Ekuklu; Kemal Kutlu
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

8.  Prognostic Significance of p27, Ki-67, and Topoisomerase lla Expression in Clinically Nonfunctioning Pancreatic Endocrine Tumors.

Authors:  Hee Jin Chang; Kenneth P. Batts; Ricardo V. Lloyd; Thomas J. Sebo; Geoffrey B. Thompson; Christine M. Lohse; Shane V. Pankratz
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

9.  Transcription Factor KLF5 Binds a Cyclin E1 Polymorphic Intronic Enhancer to Confer Increased Bladder Cancer Risk.

Authors:  Jillian M Pattison; Valeriya Posternak; Michael D Cole
Journal:  Mol Cancer Res       Date:  2016-08-11       Impact factor: 5.852

10.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.